Abstract: A method of inducing apoptosis or cell death in a leukemia cell includes subjecting the cell to a purine nucleotide analogue, LMP-420 (2-amino-6-chloro-9-[5(dihydroxyboryl)-pentyl] purine).

Abstract: A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount. Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as 131I.

Abstract: Disclosed is a method for dosimetry estimation for a region of interest at or around a surgically created resection cavity in a subject. These methods enable medical practitioners to estimate the amount of administered Radioimmunotherapy (RIT) agent needed to safely and effectively achieve a final Radiation Absorbed Dose (RAD). Furthermore, computer hardware and software are provided herein, so that the methods according to the invention may be automated for more efficient use. Also disclosed is a method of enhancing delivery of therapeutic antibodies that specifically bind to an extracellular stromal constituent of a tumor in a mammalian subject. The method comprises administering to a subject an effective dosage of a blocking antibody, said blocking antibodies specifically binding to said extracellular stromal constituent and blocking the binding of therapeutic antibodies to non-target tissue.

Abstract: A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount. Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as 131I.